clinical trial · NCT06979544
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Depression, PostpartumDepression, Post-PartumPostpartum Depression (PPD)Post-Natal DepressionPeripartum DepressionPostnatal DepressionLPCN 1154APlacebo
brief summary
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause * If LPCN 1154A reduces anxiety symptoms in subjects with severe PPD
started
Jun 16, 2025
primary completion
Jan 16, 2026
completion
Feb 17, 2026
last updated
Feb 24, 2026
official title
A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol